PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
08 Maggio 2024 - 2:30PM
PainReform Ltd. (Nasdaq: PRFX) ("
PainReform" or
the "
Company"), a clinical-stage specialty
pharmaceutical company focused on the reformulation of established
therapeutics, today announced that Ilan Hadar, Chief Executive
Officer of PainReform, participated in an interview with
Proactiveinvestors.com.
During the interview, Mr. Hadar discussed the
advantages of PRF-110 to help tackle the opioid epidemic, including
its ability to provide extended post-operative pain relief without
the use of opioids, as well as the market potential for the
product, and positive updates on the Company’s ongoing Phase 3
clinical trial.
The interview can be viewed
on Proactiveinvestors.com or on their YouTube
channel:https://www.youtube.com/@Proactive247
About Proactive InvestorsProactive
Investors is the largest financial news portal in the world focused
exclusively on small and midcap equities with offices in New York,
Toronto, Vancouver, London, Sydney and Perth. Proactive produces
more than 1,000 breaking news stories, analyst commentary, deep
dive articles and CEO interviews per week. Proactive is a certified
media provider to Google, Microsoft, Apple, Bloomberg and
Morningstar among other media outlets. For more information, go
to Proactiveinvestors.com
About PainReformPainReform is a
clinical-stage specialty pharmaceutical company focused on the
reformulation of established therapeutics. PRF-110, the Company's
lead product is based on the local anesthetic ropivacaine,
targeting the postoperative pain relief market. PRF-110 is an
oil-based, viscous, clear solution that is deposited directly into
the surgical wound bed prior to closure to provide localized and
extended postoperative analgesia. The Company's proprietary
extended-release drug-delivery system is designed to provide an
extended period of post-surgical pain relief without the need for
repeated dose administration while reducing the potential need for
the use of opiates. For more information, please visit
www.painreform.com.
Contact:Crescendo Communications,
LLCTel: 212-671-1021Email: prfx@crescendo-ir.com
Ilan HadarChief Executive OfficerPainReform
Ltd.Tel: +972-54-5331725Email: ihadar@painreform.com
Grafico Azioni PainReform (NASDAQ:PRFX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni PainReform (NASDAQ:PRFX)
Storico
Da Dic 2023 a Dic 2024